乳腺肿瘤；基因；MDR；多药耐药相关蛋白2；预后_

多药耐药相关蛋白2在乳腺癌组织中的表达及与预后关系

http://www.100md.com 《实用医技杂志》 2006年第13期

乳腺肿瘤；基因；MDR；多药耐药相关蛋白2；预后,,],乳腺肿瘤；基因；MDR；多药耐药相关蛋白2；预后,1材料与方法,2结果,3讨论,参考文献：

     [摘要] 目的：研究多药耐药相关蛋白2(Multidrug resistanceassociated protein 2，MRP2)在乳腺癌组织中的表达，评估其在乳腺癌预后中的作用。方法：采用免疫组织化学方法(Immuno Histo Chemistry，IHC)检测47例手术切除的乳腺癌组织中MRP2的表达，并分析其与临床、病理特征的关系及对预后的影响。结果：MRP2在乳腺癌组织中的阳性表达率为85.1%(40/47)，其中高表达者25例(53.2%)；MRP2表达与月经状况、肿瘤大小、腋淋巴结转移、组织分级和激素受体状况均无关(P>0.05)；KaplanMeier生存分析结果表明MRP2表达与无病生存期和总生存期均无关(P>0.05)；COX多因素分析显示只有肿瘤大小和腋淋巴结转移和无病生存期和总生存期明显相关(P<0.05)。结论：MRP2在乳腺癌组织中具有一定的表达水平，但与乳腺癌患者预后无关。

    [关键词] 乳腺肿瘤；基因；MDR；多药耐药相关蛋白2；预后

    The Prognostic Significance of Multidrug Resistanceassociated Protein 2 Expression in Primary Breast Carcinoma

    WANG Shubin1，SUI Yuping1，LIU Yajie1，et al

    (1.The Second Hospital，Jinan College，Shenzhen People's Hospital, Shenzhen，Guangdong 518020，China;

    2.Heilongjiang Province Tumor Hospital, Haerbin, Heilongjiang 150040, China；

    3.Chinese Medical Science Blood study, Tianjin 310020, China)Abstract：Objective Intrinsic and/or acquired resistance was the major obstacle to overcome in the treatment of patients with breast cancer.The aim of the present study was to investigate the relationship between the expression of multidrug resistanceassociated protein 2 (MRP2) with the clinicpathologic characteristics and the prognosis in primary breast cancer patients.Methods Expression of MRP2 in 47 breast cancer patients was determined by immunohistochemistry on formalinfixed ......

百拇医药网 http://www.100md.com/html/DirDu/2007/03/02/37/75/69.htm

您现在查看是摘要页，全文长 9699 字符。